Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02207504 | Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03793543 |
| Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer |
| completed |
| Phase 1 |
| 23 |
| Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Dec 15, 2021 |
| clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT04083196 | A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years | completed | Phase 1 | 90 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03120832 | Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients | completed | Phase 1 | 12 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT02280317 | Dose Finding Safety Study of VAL201 in Cancer Patients(VAL201-001) | completed | Phase 1 / Phase 2 | 12 | ValiRx PlcINDUSTRY | 0 | Nov 8, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04374240 | A Clinical Trial of AdNRGM Plus CB1954 in Prostate Cancer(AdUP) | completed | Phase 1 | 18 | University of BirminghamOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04574401 | A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy | completed | Phase 1 | 24 | Intuitive SurgicalINDUSTRY | 1 | Oct 22, 2021 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02914470 | Carboplatin-cyclophosphamide Combined With Atezolizumab(PROLOG) | completed | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT03136640 | ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 23 | Modra PharmaceuticalsINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01353625 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | completed | Phase 1 | 118 | CelgeneINDUSTRY | 4 | Oct 5, 2021 | clinicaltrials |
| NCT04453241 | Immunogenicity and Safety Study of NBP615 in Healthy Female | completed | Phase 1 / Phase 2 | 200 | SK Bioscience Co., Ltd.INDUSTRY | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | completed | Phase 1 | 502 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 30, 2021 | clinicaltrials |
| NCT02058550 | Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy | completed | Phase 1 | 72 | Stanford UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03394885 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer(AdORN) | completed | Phase 1 / Phase 2 | 18 | Duke UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01574937 | XL-184+Abiraterone in Post-Chemo CRPC | completed | Phase 1 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04889651 | A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers | completed | Phase 1 | 40 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Jul 22, 2021 | clinicaltrials |
| NCT02270606 | Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | completed | Phase 1 | 14 | Virginia Commonwealth UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT01912820 | Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT03332576 | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 37 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT03359850 | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | completed | Phase 1 | 17 | Tesaro, Inc.INDUSTRY | 1 | May 28, 2021 | clinicaltrials |
| NCT00916123 | Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer | completed | Phase 1 | 15 | Weill Medical College of Cornell UniversityOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT03481816 | Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 19, 2021 | clinicaltrials |
| NCT02303912 | Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer(ProGem2) | completed | Phase 1 | 25 | Imperial College Healthcare NHS TrustOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients(OCTAVE) | completed | Phase 1 | 38 | Akamis BioINDUSTRY | 2 | May 13, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT02125084 | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 | 38 | SCRI Development Innovations, LLCOTHER | 1 | May 4, 2021 | clinicaltrials |
| NCT01868386 | Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate(HypoFX) | completed | Phase 1 / Phase 2 | 32 | Timothy Showalter, MDOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02354534 | Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) | completed | Phase 1 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02269293 | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT01065662 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | completed | Phase 1 | 11 | Susana M. Campos, MDOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT04839120 | PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers | completed | Phase 1 | 8 | Med Discovery SAINDUSTRY | 1 | Apr 9, 2021 | clinicaltrials |
| NCT02458716 | Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer | completed | Phase 1 | 26 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT03813940 | Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | completed | Phase 1 | 24 | Xiamen UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01317199 | Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03507543 | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 39 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03508011 | A Study of IMP4297 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Impact Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02142608 | A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Bracco Diagnostics, IncINDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT00538668 | Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody | completed | Phase 1 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 19, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 6, 2022source: clinicaltrials